课题基金 / 基金详情

CLONING AND CHARACTERIZATION OF ADENOVIRUS RECEPTORS

CLONING AND CHARACTERIZATION OF ADENOVIRUS RECEPTORS
腺病毒受体的克隆和表征
批准号:
2442604
负责人:
Paul I Freimuth
金额:
$14.7万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-07-01 至 1998-02-28

项目摘要

项目成果

Paul I Freimuth的其他基金

相关文献

中文摘要
翻译
描述(改编自申请人摘要):腺病毒(Ad)引起 各种人体组织中的急性和持续性感染, 作为用于基因治疗的基因载体的安全性和有效性正在被 在几个临床试验中进行了评估。 宿主细胞上的受体, 介导的病毒吸附是决定 组织嗜性的个别广告血清型,也可能有助于 有效的广告单元进入机制。 然而,受体还没有被 针对超过40种已知的人Ad血清型中的任何一种进行鉴定。 识别 Ad受体的研究将增加我们对病毒发病机制的理解, 允许将来开发针对受体的抗病毒治疗方案 这可能会阻止感染,并允许选择合适的Ad 在基因治疗中用作组织特异性载体的血清型。 作为第一 为了进一步表征Ad受体,我们建议克隆 Ad2受体(血清型2),并表征其结构和功能, 人体细胞 将开发抗体和核酸探针, 受体的生物化学表征和研究受体 在不同的人类细胞类型中表达。
英文摘要
DESCRIPTION (Adapted from Applicant's Abstract): Adenoviruses (Ads) cause acute and persistent infections in a variety of human tissues, and their safety and efficacy as gene vectors for use in gene therapy is being evaluated in several clinical trials. The receptor on host cells that mediates virus adsorption is one of several factors that determines the tissue tropism of individual Ad serotypes, and may also contribute to the efficient Ad cell-entry mechanism. However, receptors have not been identified for any of the over 40 known human Ad serotypes. Identification of Ad receptors will increase our understanding of viral pathogenesis, will permit the future development of antiviral regimens directed at the receptor which might block infection, and will allow the selection of appropriate Ad serotypes for use as tissue specific vectors in gene therapy. As a first step towards the characterization of Ad receptors, we propose to clone the receptor for Ad2 (serotype 2) and characterize its structure and function on human cells. Antibodies and nucleic acids probes will be developed for biochemical characterization of the receptor and to study receptor expression in different human cell types.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LABELING OF ADENOVIRUS 12 KNOB
LABELING OF ADENOVIRUS 12 KNOB
LABELING & CRYSTALLIZATION OF ADENOVIRUS A12 KNOB: RECEPTORS
LABELING OF ADENOVIRUS 12 KNOB